Microbiological aspects of pulmonary infections in mucoviscidosis;Aspects microbiologiques des infections pulmonaires au cours de la mucoviscidose

Medecine Therapeutique

Volumn 3, Issue 6, 1997, Pages 451-457

  Chabanon, Gérard ^a   Segonds, Christine ^a   Marty, Nicole ^a   Dournes, Jean Luc ^a   Agueda, Louis ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ASPERGILLUS; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; ESCHERICHIA COLI; HUMAN; LEGIONELLA; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; VIRUS INFECTION;

EID: 0030792994     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Gilligan P.H. 1991. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4 : 35-51.
2. Anderson D.H. 1949. Therapy and prognosis of fibrocystic disease of the pancreas. Pediatrics 3 : 406-417.
3. Høiby N. 1982. Microbiology of lung infection in CF patients. Acta Paediatr Scand 301 (suppl.) : 33-54
4. Montalembert (de) M., Boukadida J., Berche P. 1991. Aspects bactériologiques de la mucoviscidose. Rev Fr Lab 220 : 57-64.
5. Chabanon G., et al. 1997. Epidemiology of the primary acquisition of Pseudomonas aeruginosa by cystic fibrosis patients : a retrospective study. 15th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) Paris 22-23 mai 1997.
6. Aly R., Levit S 1987. Adherence of Staphylococcus aureus to squamous epithelium : role of fibronectin and teichoic acid. Rev Infect Dis 9 (suppl. 4): 341-350.
7. Döring G., Knight R., Bellon G. 1995. Immunology of cystic fibrosis. In : Hoddson M.E., Geddes D.M., eds. Texbook of cystic fibrosis. Londres : Chapman and Hall, 99-130.
8. Boxerbaum B., Jacobs M.R., Cechner R.L. 1988. Prevalence and significance of methicillin resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmon 4 . 159-163.
9. Zuelzer W.W., Newton W.A. Jr. 1950. The pathogenesis of fibrocystic disease of the pancreas : a study of 36 cases with special reference to pulmonary lesions. Pediatrics 4 : 53-69.
10. Woods D.E., Strauss D C , Johanson W.C., Bass J.A. 1981. Role of fibronectin in the prevention of adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. J Infect Dis 143 : 786-790.
11. Bauernfeind A., Emminger G., Horl G., Lorbeer H., Przylenk B., Weisslein-Pfister C. 1987. Selective pressure of antistaphylococcal chemotherapeutics in favor of Pseudomonas aeruginosa in cystic fibrosis. Infection 15 : 469-470.
12. Doggett R.G., Harrison G.M., Stillwell R.N., Wallis E.S. 1966. An atypical Pseudomonas aeruginosa associated with cystic fibrosis of the pancreas. J Pediatr 68 : 215-221.
13. Pasquier C., Dournes J.L, Chabanon G , Marty N. 1996. The biosynthesis of Pseudomonas aeruginosa aiginate regulation of a virulence factor. Bull Inst Pasteur 94 : 139-149.
14. Berry A., Devault J D., Chakrabarty A.M. 1989. High osmolarity is a signal for enhanced algD transcription in mucoid and non mucoid Pseudomonas aeruginosa strains. J Bact 171 : 2312-2317
15. Marty N., Dournes J.L., Chabanon G., Montrozier H. 1992. Influence of nutrient media on the chemical composition of the exopolysaccharide from mucoid and non mucoid Pseudomonas aeruginosa. FEMS Microbiol Lett 98 : 35-44.
16. Aubry J C., Marty N., Dournes J.L , Didier A., Chabanon G., Léophonte P. 1995. Follow-up of Pseudomonas aeruginosa infection in idiopathic bronchectasies : phenotypic and genotypic characteristics. Am J Respir Crit Care Med 151 : A467.
17. Costerton J.W., Lam J., Chan R. 1983. The role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections. Rev Infect Dis 5 : S867-S873.
18. Baltimore R.S., Mitchell M. 1980. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa . comparaison of susceptibility to opsonic antibody in mucoid and non mucoid strains. J Infect Dis 141 : 238-247.
19. Marty N., et al. 1977. The role of the Pseudomonas aeruginosa exopolysaccharide in adherence to human tracheal cells. J Med Microbiol (sous presse).
20. Doring G., Albus A., Høiby N. 1988. Immunologic aspects of cystic fibrosis. Chest 94 : S1095-S1145.
21. Michel-Briand Y., Grandguillot M. 1991. Facteurs de pcthogénicité de Pseudomonas aeruginosa et critères permettant de valider son pouvoir pathogène. Lettre Infect 1 : 3-6.
22. Pier G.B., Grout M., Zaidi T.S. 1996. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271 : 64-67.
23. Wilson C.B. 1996. The immune system : the devie within on the Good Guy. Pediatr Pulmon 13 (suppl.) : 75.
24. Moss R. 1996. Pathways on inflammation in cystic fibrosis. Pediatr Pulmon 1 (suppl.) : 158-159
25. Wiener-Kronish J.P., Frank D.W., Fleiszig M J., Sawa T. 1996 The different host responses to Pseudomonas aeruginosa : the implication of therapy. Pediatr Pulmon 13 (suppl.): 144-145.
26. Høiby N., Koch C. 1990. Pseudomonas aeruginosa infection in CF and its management. Thorax 45 : 881-884.
27. Stutman H.R. 1996. Approch to CF related pulmonary infection in the US. In : Cystic fibrosis pulmonary infections. Basel . Berkhauser Verlag, 128-134.
28. Ramsey B.W., Pople M., Warren J.W. 1994. Pulmonary exacerbation : how do we define it ? In : 8th Annual North American CF Conference Proceedings. New York : Wiley-Liss, 105.
29. Navarro J 1993. Vision actuelle et perspectives de la thérapeutique dans la mucoviscidose. Bull Acad Nat Med 177 : 413-424.
30. Bingen E., et al. 1992. Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 31 : 2589-2593.
31. Godart C., Plesiat R., Michel-Briand Y. 1993. Persistance of Pseudomonas aeruginosa strains in seven cystic fibrosis patients followed over 20 months. Eur J Med 2 : 117-120
32. Dournes J.L., Marty N., Chabanon G. 1994. Pseudomonas aeruginosa, ses marqueurs épidémiologiques. Lettre Infect 9 : 432-439
33. Isles A., et al. 1984 Pseudomonas cepacia infection in cystic fibrosis . an emerging problem J Pediatr 104 . 206-210.
34. Saiman O., Martone W., Jarvis W 1987 The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis. Eur J Epidemiol 3 : 336-342.
35. Govan J R., et al 1993. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342 : 15-19.
36. Lewin L.O., Byard P.J , Davis P.B. 1990. Effect of Pseudomonos colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 43 : 125-131.
37. Segonds C., Chabanon G., Couetdic G., Michel-Briand Y , Bingen E., and the French Observatoire Burkholderia cepacia Study Group. 1996. Epidemiology of pulmonary colonization with Burkholderia cepacia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 15 : 841-842.
38. Anonyme. 1992. Pseudomonas cepacia more than a harmless commensal. Lancet 339 : 1385-1386
39. Sajjan U , Corey M., Karmali M., Forstner J. 1992. Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cytic fibrosis. J Clin Invest 89 : 648-656.
40. Goldstein R. 1995. Structurally variant classes of pilus appendage fibers co-expression from Burkholderia cepacia. J Bad 177 : 1039-1052.
41. + Pseudomonas (Burkholderia) cepacia causing CF centre epidemia in North America and Britain. Nature Medicine 1 : 661-666.
42. Saiman L., Cacalano G., Prince A. 1990. Pseudomonas cepacia adherence to respiratory epithelial cells is enhanced by Pseudomonas aeruginosa. Infect Immun 58 : 2578-2584.
43. Meyer J.M., Hohnadel D., Halle F. 1989. Cepabactin from Pseudomonas cepacia, a new type of siderophore. J Gen Microbiol 135 : 1479-1487.
44. McKevitt A.I., Bajaksouzian S., Klinger J.D, Woods D.E. 1989. Purification and characterization of a extracellular protease from Pseudomonas cepacia. Infect Immun 57 771-778
45. Gessner A.R., Mortensen J.E. 1990. Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis. J Med Microbiol 33 : 115-120.
46. Cerentola S., Marty N., Montrozier H. 1996. Structural studies of the acidic exopolysaccharide produced by a mucoid strain of Burkholderia cepacia isolated from cystic fibrosis. Carbohydrate Research 285 : 59-67.
47. Pasquier C., Marty N., Dournes J L., Chabanon G., Pipy B. 1997 Implication of neutral polysaccharides associated to alginate in inhibition of murine macrophages response to Pseudomonas aeruginosa. FEMS Microbiol Lett 147 : 195-204.
48. Speert D., Bond Y., Woodman R.C., Curnutte J T. 1994. Infection with Pseudomonas cepacia in chronic granulomatous disease : role of non-oxydative killing by neutrophils in host defense J Clin Invest 170 : 1524-1531.
49. Nelson J.W., Butler S.L, Krieg D., Govan J R.W. 1994. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 8 . 89-98.
50. Segonds C., Marty N., Agueda L., Chabanon G. 1995. Pseudomonas cepacia : la percée d'un opportuniste. Rev Fr Labo 274 : 87-93.
51. Segonds C., Chabanon G. 1997. Polymerase chain reaction (PCR) restriction fragment analysis of 16rDNA as an identifical tool for Burkholderia cepacia and closely related species recovered from patients with cystic fibrosis. 21st European Cystic Fibrosis Conference. Davos 1-6 juin 1997.
52. Bingen E., et al. 1993. Arbitrarily primed polymerase chain reaction is a rapid method to differentiate crossed from independant Pseudomonas cepacia infections in cystic fibrosis patients J Clin Microbiol 31 : 2589-2593.
53. Segonds C., et al 1997. Genotypic analysis of Burkholderia cepacia isolates in 13 French cystic fibrosis centres. J Clin Microbiol 35 (sous presse)
54. Chatelut M., Dournes J.L., Chabanon G , Marty N. 1995. Epidemiological typing of Xanthomonas maltophilia by PCR. J Clin Microbiol 33 : 912-914.
55. Kinney J.S., Little B J., Yolken R.H , Rosenstein B.J. 1989. Mycobacterium avium complex in a patient with cystic fibrosis : disease vs colonization. Pediatr Infect Dis 8 : 393-396.
56. Abman S.H., Ogle J.W., Bulter-Simon N., Rumack C.M., Accurso F.J. 1988. Role of respiratory syncitial virus in early hospitalization for respiratory distress of young infants with cystic fibrosis. J Pediatr 133 : 826-830.